Rare Disease Report

Pfizer's Rare Disease Programs

NOVEMBER 09, 2015
Bert Bruce, MBA



 At NORD's Rare Diseases and Orphan Products Breakthrough Summit, we talked with Bert Bruce,  MBA, vice president of Rare Disease Commercial Development at Pfizer, about some of the programs  his company has in development - including drugs to treat patients with Duchenne muscular dystrophy, sickle cell disease, and hemophilia B.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.